Literature DB >> 22592348

Diagnostic value of optical coherence tomography for intracranial pressure in idiopathic intracranial hypertension.

Maren Skau1, Hanne Yri, Birgit Sander, Thomas A Gerds, Dan Milea, Rigmor Jensen.   

Abstract

BACKGROUND: Idiopathic intracranial hypertension (IIH) is a condition of raised intracranial pressure (ICP) in the absence of space-occupying lesions or other known etiology. It primarily affects young obese females, and potentially causes permanent visual loss due to papilledema and secondary optic atrophy. The aim of this study was to evaluate the diagnostic value of optical coherence tomography (OCT) as a marker for CSF opening pressure in patients with idiopathic intracranial hypertension (IIH).
METHODS: We conducted a case-control study of 20 newly diagnosed, 21 long-term IIH patients, and 20 healthy controls. Investigations included measurement of peripapillary retinal nerve fiber layer thickness (RNFLT) and total retinal thickness (RT), automated visual field testing, and measurement of CSF opening pressure. An OCT elevation diagram was developed as a new diagnostic tool. The diagnostic ability of OCT as a marker of increased ICP (> 25 cmH(2)O) was investigated using multiple regression and receiver operating characteristic (ROC) curves.
RESULTS: OCT elevation diagrams showed that in 60 % of patients newly diagnosed with IIH and in 10 % of patients with long-term IIH, 50 % or more of the OCT scans (RT and RNFLT) were above normal. The percentage of abnormal OCT scans was significantly associated with increased ICP (p < 0.0001). Estimated areas under the ROC curves increased from 77.1 to 86.9 by including OCT in multiple regressions. Autoperimetry pattern standard deviation was significantly increased (p = 0.0005) and mean deviation was significantly decreased (p = 0.0005) in IIH patients as compared to healthy controls.
CONCLUSIONS: Increased peripapillary retinal thickness measured by OCT is associated with increased ICP in newly diagnosed IIH patients. OCT may thus serve as a valuable supplement to subjective assessment of papilledema in patients suspected of having IIH. In long-term IIH patients who have previously been treated, OCT appears to be of limited value in predicting ICP.

Entities:  

Mesh:

Year:  2012        PMID: 22592348     DOI: 10.1007/s00417-012-2039-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  29 in total

1.  Laser scanning tomography of the optic nerve vs CSF opening pressure in idiopathic intracranial hypertension.

Authors:  J G Heckmann; M Weber; A G Jünemann; B Neundörfer; C Y Mardin
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

2.  Optical coherence tomography as a tool for monitoring pediatric pseudotumor cerebri.

Authors:  Mays A El-Dairi; Sandra Holgado; Thomas O'Donnell; Edward G Buckley; Sanjay Asrani; Sharon F Freedman
Journal:  J AAPOS       Date:  2007-10-24       Impact factor: 1.220

3.  OCT measurements in patients with optic disc edema.

Authors:  Marcel N Menke; Gilbert T Feke; Clement L Trempe
Journal:  Invest Ophthalmol Vis Sci       Date:  2005-10       Impact factor: 4.799

4.  Quantification of nerve fiber layer thickness in normal and glaucomatous eyes using optical coherence tomography.

Authors:  J S Schuman; M R Hee; C A Puliafito; C Wong; T Pedut-Kloizman; C P Lin; E Hertzmark; J A Izatt; E A Swanson; J G Fujimoto
Journal:  Arch Ophthalmol       Date:  1995-05

5.  Optic disc edema in raised intracranial pressure. I. Evolution and resolution.

Authors:  M S Hayreh; S S Hayreh
Journal:  Arch Ophthalmol       Date:  1977-07

6.  Retinal nerve fiber layer evaluation by optical coherence tomography in Leber's hereditary optic neuropathy.

Authors:  Piero Barboni; Giacomo Savini; Maria Lucia Valentino; Pasquale Montagna; Pietro Cortelli; Anna Maria De Negri; Federico Sadun; Stefania Bianchi; Lora Longanesi; Maurizio Zanini; Antonello de Vivo; Valerio Carelli
Journal:  Ophthalmology       Date:  2005-01       Impact factor: 12.079

7.  Intracranial pressure, conductance to cerebrospinal fluid outflow, and cerebral blood flow in patients with benign intracranial hypertension (pseudotumor cerebri).

Authors:  F Gjerris; P Soelberg Sørensen; S Vorstrup; O B Paulson
Journal:  Ann Neurol       Date:  1985-02       Impact factor: 10.422

8.  Differentiating optic disc edema from optic nerve head drusen on optical coherence tomography.

Authors:  Lenworth N Johnson; Meredith L Diehl; Chuck W Hamm; Drew N Sommerville; Gregory F Petroski
Journal:  Arch Ophthalmol       Date:  2009-01

Review 9.  Optical coherence tomography in optic neuritis and multiple sclerosis: a review.

Authors:  K Kallenbach; J Frederiksen
Journal:  Eur J Neurol       Date:  2007-08       Impact factor: 6.089

10.  Normal age-related decay of retinal nerve fiber layer thickness.

Authors:  Rajul S Parikh; Shefali R Parikh; G Chandra Sekhar; S Prabakaran; J Ganesh Babu; Ravi Thomas
Journal:  Ophthalmology       Date:  2007-05       Impact factor: 12.079

View more
  19 in total

1.  CSF pressure, papilledema grade, and response to acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial.

Authors:  Jorge C Kattah; John H Pula; Luis J Mejico; Michael P McDermott; Mark J Kupersmith; Michael Wall
Journal:  J Neurol       Date:  2015-07-10       Impact factor: 4.849

Review 2.  Noninvasive methods of detecting increased intracranial pressure.

Authors:  Wen Xu; Patrick Gerety; Tomas Aleman; Jordan Swanson; Jesse Taylor
Journal:  Childs Nerv Syst       Date:  2016-06-28       Impact factor: 1.475

3.  Intracranial pressure patterns in children with craniosynostosis utilizing optical coherence tomography.

Authors:  Jordan W Swanson; Wen Xu; Gui-Shuang Ying; Wei Pan; Shih-Shan Lang; Gregory G Heuer; Scott P Bartlett; Jesse A Taylor
Journal:  Childs Nerv Syst       Date:  2019-12-17       Impact factor: 1.475

4.  The application of optical coherence tomography in neurologic diseases.

Authors:  Ramiro S Maldonado; Pradeep Mettu; Mays El-Dairi; M Tariq Bhatti
Journal:  Neurol Clin Pract       Date:  2015-10

5.  Baseline OCT measurements in the idiopathic intracranial hypertension treatment trial, part II: correlations and relationship to clinical features.

Authors:  Peggy Auinger; Mary Durbin; Steven Feldon; Mona Garvin; Randy Kardon; John Keltner; Mark J Kupersmith; Patrick Sibony; Kim Plumb; Jui-Kai Wang; John S Werner
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-11-04       Impact factor: 4.799

6.  Papilledema Outcomes from the Optical Coherence Tomography Substudy of the Idiopathic Intracranial Hypertension Treatment Trial.

Authors: 
Journal:  Ophthalmology       Date:  2015-07-18       Impact factor: 12.079

7.  Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension.

Authors:  Vivek Vijay; Susan P Mollan; James L Mitchell; Edward Bilton; Zerin Alimajstorovic; Keira A Markey; Anthony Fong; Jessica K Walker; Hannah S Lyons; Andreas Yiangou; Georgios Tsermoulas; Kristian Brock; Alexandra J Sinclair
Journal:  JAMA Ophthalmol       Date:  2020-12-01       Impact factor: 7.389

Review 8.  Perspectives on diagnosis and management of adult idiopathic intracranial hypertension.

Authors:  Irini Chatziralli; Panagiotis Theodossiadis; George Theodossiadis; Ioannis Asproudis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-04-04       Impact factor: 3.117

Review 9.  Pathogenesis and Evaluation of the Effects of Idiopathic Intracranial Hypertension on the Optic Nerves.

Authors:  Nada Elsaid; Omar Ahmed; Tamer Belal; Ahmed Razek; Ahmed Azab
Journal:  Neuroophthalmology       Date:  2020-06-16

10.  Evaluation of Optical Coherence Tomography to Detect Elevated Intracranial Pressure in Children.

Authors:  Jordan W Swanson; Tomas S Aleman; Wen Xu; Gui-Shuang Ying; Wei Pan; Grant T Liu; Shih-Shan Lang; Gregory G Heuer; Phillip B Storm; Scott P Bartlett; William R Katowitz; Jesse A Taylor
Journal:  JAMA Ophthalmol       Date:  2017-04-01       Impact factor: 7.389

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.